Abstract
Peritoneal metastases from gastric cancer (PM-GC) have a detrimental prognostic impact on survival and there is a lack of consensus regarding treatment. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a chance for prolonged survival as compared to standard chemotherapy. This study aims to present our experience in the management of GC with CRS and HIPEC. This is a single-centre retrospective study. Patients were divided into two groups: patients with GC at high risk for developing PM-GC (adjuvant HIPEC group) and patients with PM-GC or positive peritoneal cytology (therapeutic CRS and HIPEC group). Overall survival (OS) and disease-free survival (DFS) were considered as outcome measures. A total of 41 patients with a GC primary received surgery and HIPEC: 14 patients (34.1%) were in the adjuvant HIPEC group, while 27 patients (65.9%) were in the therapeutic CRS and HIPEC group. In the adjuvant HIPEC group, the 1- and 3-year OS were 85.7% and 71.4%, while 1- and 3-year DFS were 71.4% and 64.3%, respectively. In the therapeutic CRS and HIPEC group, OS was 60.3% and 35.1% at 1 and 3 years, whereas 1- and 3-year DFS were 38% and 32.6%, respectively. Univariate survival analysis of patients in the therapeutic CRS and HIPEC group showed that the presence of lymph node metastasis and signet ring cell histology predicted worse OS, while PCI > 12 and lymph node metastasis were associated with decreased DFS. Treatment of highly selected patients with GC at high risk of peritoneal recurrence or established PM with CRS and HIPEC showed satisfactory results in terms of OS and DFS.
Similar content being viewed by others
References
Thomassen I, Bernards N, Van GYR, Jacobs EM, Lemmens VE, De HIH (2014) Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol. https://doi.org/10.3109/0284186X.2013.850740
Badgwell B, Das P, Ajani J (2017) Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. https://doi.org/10.1186/s13045-017-0517-9
Thomassen I, VanGestel YR, Van Ramshorst B et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 628:622–628. https://doi.org/10.1002/ijc.28373
Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 multicentric prospective study. Cancer 1:358–363
Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF (2006) Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243(2):189–195. https://doi.org/10.1097/01.sla.0000197382.43208.a5
Yarema R, Ohorchak M, Hyrya P (2020) Gastric cancer with peritoneal metastases: efficiency of standard treatment methods. WJGO. 12(5):569–581
Ikoma N, Blum M, Chiang Y et al (2016) Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. https://doi.org/10.1245/s10434-016-5409-7
Ikoma N, Chen H, Wang X et al (2017) Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol 24(March):2679–2687. https://doi.org/10.1245/s10434-017-5838-y
Spolverato G, Ejaz A, Kim Y et al (2014) Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg 219(4):664–675. https://doi.org/10.1016/j.jamcollsurg.2014.03.062
Yonemura Y, Bandou E, Kazuo K et al (2003) Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 12(3):635–648
Homma Y, Ushida S, Yamada M, Kobayashi H (2009) Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol 2010:455–460. https://doi.org/10.1245/s10434-009-0764-2
Coccolini F, Cotte E, Glehen O et al (2014) Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 40(1):12–26. https://doi.org/10.1016/j.ejso.2013.10.019
Liu Y, Du Y, Chen B (2019) Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials. J Int Med Res. https://doi.org/10.1177/0300060519882545
Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. EJSO 42:1123–1131. https://doi.org/10.1016/j.ejso.2016.03.016
Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377. https://doi.org/10.1245/s10434-010-1039-7
Yang X, Huang C, Suo T, Mei L, Yang G (2010) cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Annu Surg Oncol 2011:1575–1581. https://doi.org/10.1245/s10434-011-1631-5
Rudloff U, Langan RC, Mullinax JE, Beane JD, Seth M (2014) Impact of maximal cytoreductive surgery plus regional heated intra-peritoneal chemotherapy (HIPEC) on outcomes of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA Trial. J Surg Oncol 110(3):275–284. https://doi.org/10.1002/jso.23633.Impact
Bonnot PE, Piessen G, Kepenekian V et al (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37(23):2028–2040. https://doi.org/10.1200/JCO.18.01688
Fugazzola P, Coccolini F, Montori G et al (2017) Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis. J Gastrointest Oncol 8(3):572–582. https://doi.org/10.21037/jgo.2017.03.11
Badgwell B, Ikoma N, Murphy MB, Wang X (2021) A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol 28(1):258–264. https://doi.org/10.1245/s10434-020-08739-5
Smyth EC, Verheij M, Allum W et al (2016) clinical practice guidelines Gastric cancer: ESMO Clinical Practice Guidelines for clinical practice guidelines. ESMO Updat Clin Pract Guidel 27(August):v38–v49. https://doi.org/10.1093/annonc/mdw350
Clinical N, Guidelines P, Guidelines N. Gastric Cancer. Published online 2021.
Consensus C, Group W (2019) The Chicago consensus on peritoneal surface malignancies: management of gastric metastases. Annu Surg Oncol 2020:1768–1773. https://doi.org/10.1245/s10434-020-08320-0
Gilly FN, Cotte E, Brigand C, Monneuse O (2006) Quantitative prognostic indices in peritoneal carcinomatosis. EJSO 32:597–601. https://doi.org/10.1016/j.ejso.2006.03.002
Jacquet P, Sugarbaker P (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374
Dindo D, Demartines N, Clavien P (2004) Classification of surgical complications 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
Sugarbaker PH (2007) Peritonectomy procedures. Perit Carcinomatosis A Multidiscip Approach 221(1):247–264. https://doi.org/10.1007/978-0-387-48993-3_15
Bernards N, Creemers GJ, Nieuwenhuijzen GAP, Bosscha K, Pruijt JFM, Lemmens VEPP (2013) No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol 24(12):3056–3060. https://doi.org/10.1093/annonc/mdt401
Yan TD, Mbbs M, Black D et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Annu Surg Oncol 14(10):2702–2713. https://doi.org/10.1245/s10434-007-9487-4
Glehen O, Passot G, Villeneuve L et al (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14(1):1–10. https://doi.org/10.1186/1471-2407-14-183
Kang L, Mok K, Liu S et al (2013) Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. J Chinese Med Assoc 76(8):425–431. https://doi.org/10.1016/j.jcma.2013.04.004
Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B (2021) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 34(11):1246–1252. https://doi.org/10.1016/j.ejso.2007.12.003
Rau B, Brandl A, Thuss P et al (2019) The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer 22(6):1226–1237. https://doi.org/10.1007/s10120-019-00969-1
Manzanedo I, Pereira F, Caro CR, Gutie A, Martı G (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol 26:2615–2621. https://doi.org/10.1245/s10434-019-07450-4
Koemans WJ, Van Der KRT, Boot H et al (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer 19:1–8
Benizri EI, Ph D, Bereder J, Rahili A, Bernard J, Benchimol D (2013) Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer. Am J Surg 205(6):668–673. https://doi.org/10.1016/j.amjsurg.2012.06.009
White MG, Kothari A, Ikoma N, Murphy MB (2020) Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08842-7
Stark AP, Ikoma N, Chiang YJ et al (2019) Characteristics and survival of gastric cancer patients with pathologic complete response to preoperative therapy. Ann Surg Oncol 26(11):3602–3610. https://doi.org/10.1245/s10434-019-07638-8
Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B (2021) Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi- institutional cohort from PSOGI. Eur J Surg Oncol 47(1):172–180. https://doi.org/10.1016/j.ejso.2020.10.006
Wang R, Song S, Harada K et al (2020) Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. https://doi.org/10.1136/gutjnl-2018-318070
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
NA and SMa: conceptualisation, data analysis, writing, review and editing; FB: conceptualisation, data collection; PF: data collection; MP, GM and FC: conceptualisation, review and editing, supervision; SM, BM, SM, LC, AL and LA: supervision. All the authors reviewed the final version of the paper and gave final approval for submission.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interest.
Research involving human participants and/or animals
This study was conducted under the WMA declaration of helsinki and is compliant with Ethical Standards, Research involving human participants and/or animals.
Informed consent
Due to the retrospective nature, consent for participation in the study was waived, and no direct referral to patient data is evident.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Allievi, N., Bianco, F., Pisano, M. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience. Updates Surg 75, 159–167 (2023). https://doi.org/10.1007/s13304-022-01399-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13304-022-01399-y